Therapy Detail

Therapy Name AMC303
Synonym
Therapy Description

AMC303 is an allosteric inhibitor of CD44v6, the co-receptor of c-MET, RON, and VEGFR2, which may result in decreased cell invasion and migration, and tumor regression (Cancer Res 2017;77(13 Suppl):Abstract nr 4911).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AMC303 AMC303 is an allosteric inhibitor of CD44v6, the co-receptor of c-MET, RON, and VEGFR2, which may result in decreased cell invasion and migration, and tumor regression (Cancer Res 2017;77(13 Suppl):Abstract nr 4911).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable AMC303 Preclinical - Cell line xenograft Actionable In a preclinical study, AMC303 resulted in decreased cell invasion and migration in solid tumor cell lines in culture and tumor regression of metastatic lesions of the liver in xenograft models (Cancer Res 2017;77(13 Suppl):Abstract nr 4911). detail...
Clinical Trial Phase Therapies Title Recruitment Status